Armata Pharmaceuticals, Inc. (ARMP)
$5.33-$0.06 (-1.10%) Today
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Tax withholding / forfeiture | 1 | 14,041 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
15 Form 4 filings on record, the earliest from Oct 3, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Deborah Birx - Officer | Tax withholding / forfeiture | Common Stock | 14,041 | $4.26 | $60K | |
| Daniel B. Gilmer - Director | Grant or award | Stock Options (Right to Buy) | 51,280 | $0.00 | - | |
| Pierre Kyme - Officer | Tax withholding / forfeiture | Common Stock | 1,030 | $10.54 | $11K | |
| Deborah Birx - Officer | Tax withholding / forfeiture | Common Stock | 4,919 | $10.54 | $52K | |
| Robin Kramer - Director | Grant or award | Stock Options (Right to Buy) | 25,640 | $0.00 | - | |
| Pierre Kyme - Officer | Grant or award | Stock Options (Right to Buy) | 183,142 | $0.00 | - | |
| David Duane House - Officer | Grant or award | Stock Options (Right to Buy) | 109,885 | $0.00 | - | |
| Joseph M. Patti - Director | Grant or award | Stock Options (Right to Buy) | 25,640 | $0.00 | - | |
| Todd C. Peterson - Director | Grant or award | Stock Options (Right to Buy) | 25,640 | $0.00 | - | |
| Kostas D. Odysseas - Director | Grant or award | Stock Options (Right to Buy) | 25,640 | $0.00 | - | |
| Deborah Birx - Officer | Grant or award | Stock Options (Right to Buy) | 421,226 | $0.00 | - | |
 Sarah J. Schlesinger - Director | Grant or award | Stock Options (Right to Buy) | 25,640 | $0.00 | - | |
| Jules Haimovitz - Director | Grant or award | Stock Options (Right to Buy) | 25,640 | $0.00 | - | |
| Deborah Birx - Officer | Tax withholding / forfeiture | Common Stock | 13,637 | $2.27 | $31K | |
| David Duane House - Officer | Grant or award | Stock Options (Right to Buy) | 75,000 | $0.00 | - |
Armata Pharmaceuticals, Inc. (ARMP) had 1 insider filing in the last 90 days, with the most recent on 2026-07-14. The full record for ARMP runs to 15 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ARMP were filed in the last 90 days.
No insider sales of ARMP were filed in the last 90 days.
This page tracks ARMP Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ARMP to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
